


1/39

FIGURE 1A



SUBSTITUTE SHEET (RULE 26)


09/914872

WO 00/51642

PCT/US00/05633

2/39

FIGURE 1B



SUBSTITUTE SHEET (RULE 26)


09/914872

WO 00/51642

PCT/US00/05633

3/39

FIGURE 1C




SUBSTITUTE SHEET (RULE 26)

4/39

Size: 0.6360 mg  
Method: 10 DEG C/MIN AMB TO 300  
Comment: SEALED PAN


FIGURE 2A



SUBSTITUTE SHEET (RULE 26)

5/39

Size: 1.7840 mg  
Method: 10 DEG C/MIN AMB TO 300  
Comment: SEALED PAN




SUBSTITUTE SHEET (RULE 26)

6/39

Size: 1.4230 mg  
Method: 10 DEG C/MIN AMB TO 300  
Comment: SEALED PAN


FIGURE 2C



SUBSTITUTE SHEET (RULE 26)

Size: 1.0400 mg  
Method: 10 DEG C/MIN AMB TO 300  
Comment: SEALED PAN

FIGURE 2D



SUBSTITUTE SHEET (RULE 26)


09/914872

WO 00/51642

PCT/US00/05633

8/39


FIGURE 3A



SUBSTITUTE SHEET (RULE 26)

9/39


FIGURE 3B



SUBSTITUTE SHEET (RULE 26)


10/39

FIGURE 3C



SUBSTITUTE SHEET (RULE 26)


11/39



SUBSTITUTE SHEET (RULE 26)

12/39

FIGURE 4



SUBSTITUTE SHEET (RULE 26)

09/914872

WO 00/51642

PCT/US00/05633

13/39





FIGURE 5


SUBSTITUTE SHEET (RULE 26)

Size: 3.3010 mg  
Method: 10 deg ramp to 300 deg



15/39


FIGURE 7



SUBSTITUTE SHEET (RULE 26)


16/39

FIGURE 8



17/39


FIGURE 9



SUBSTITUTE SHEET (RULE 26)

18/39


FIGURE 10



SUBSTITUTE SHEET (RULE 26)


19/39

FIGURE 11



20/39

FIGURE 12



SUBSTITUTE SHEET (RULE 26)




FIGURE 14






FIGURE 15




24/39

FIGURE 16




25/39

FIGURE 17




26/39

FIGURE 18



27/39

FIGURE 19



28/39

FIGURE 20






FIGURE 21

INEL



SUBSTITUTE SHEET (RULE 26)

FIGURE 22



SUBSTITUTE SHEET (RULE 26)

31/39

## FIGURE 23




FIGURE 24

## Baseline Characteristics

Variable Mean ( SD)	Placebo n=55		EPL 25 QD		EPL 25 BID		EPL 50 QD		EPL 100 QD		SPIRO 25 QD		n=46	p-value
EPLERENONE														
Age	60	62	61	62	61	62	61	61	61	62	62	62	62	0.9
M/I (%)	80/20	76/24	81/19	80/20	80/20	78/22	78/22	78/22	78/22	78/22	78/22	78/22	78/22	0.9
NYI IA II III (%)	100	97	94	100	100	98	98	98	98	98	98	98	98	100
NYI IA IV (%)	0	3	6	0	0	2	2	2	2	2	0	0	0	
II (%)	29	29	29	30	30	30	30	30	30	30	30	30	30	0.8
IIR (BPM)	74	76	76	73	73	76	76	76	76	76	76	76	76	0.7
SBP (mm Hg)	127	124	128	125	125	129	129	129	129	129	130	130	130	0.4
DBP (mm Hg)	78	78	79	78	78	78	78	78	78	78	78	78	78	1.0
K' (mmol/L)	4.48	4.38	4.28	4.34	4.34	4.38	4.38	4.38	4.38	4.38	4.45	4.45	4.45	0.2
Creatinine (pmol/L)	107	109	104	107	107	109	109	109	109	109	107	107	107	0.7
32/39														

SUBSTITUTE SHEET (RULE 26)


33/39

## FIGURE 25

Concurrent Medications		
Category	% Patients	Avg. Dose (mg/day)
• ACE Inhibitor		
Captopril	30	62
Enalapril	30	15
Lisinopril	15	15
• Loop Diuretic		
Furosemide	85	50
• Other		
Digitalis	55	
beta-Blockers	35	
Aspirin	35	
Anticoagulants	35	
Potassium Supplements	25	
Calcium Antagonist	25	


34/39

FIGURE 26



35/39


FIGURE 27



SUBSTITUTE SHEET (RULE 26)


36/39

FIGURE 28




SUBSTITUTE SHEET (RULE 26)

FIGURE 29



SUBSTITUTE SHEET (RULE 26)

FIGURE 30



39/39

## FIGURE 31

Study Schematic For Biological Evaluation II: Multicenter, Randomized  
Double-Blind, Parallel Group Trial  
Minimum Trial Duration 1.012 Deaths

